Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 1023-1038, December 2008

Receptor tyrosine kinase inhibitors in thyroid cancer

  • Massimo Santoro, MD, PhD (Professor of Pathology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39-081-7463056; Fax: +39-081-7463037.

Istituto di Endocrinologia ed Oncologia Sperimentale CNR, 80131 Naples, Italy c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita' Federico II, 80131 Naples, Italy

Istituto di Endocrinologia ed Oncologia Sperimentale CNR, 80131 Naples, Italy c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita' Federico II, 80131 Naples, Italy

Dipartimento di Studi delle Istituzioni e dei Sistemi Territoriali, Universita' ‘Parthenope’, 80133 Naples, Italy

Dipartimento di Biologia e Patologia Cellulare e Molecolare, ‘L. Califano’, Università Federico II, via S. Pansini 5, 80131 Naples, Italy

Thyroid cancer is frequently associated with the oncogenic conversion of receptor tyrosine kinases (RTKs) or their downstream signalling molecules. Hence, there is a strong biological rationale for assessing the efficacy of RTK blockade to treat patients who are resistant to or not candidates for treatment with radioactive iodine. The first results of clinical trials based on the use of RTK inhibitors in thyroid cancer patients have recently been published. Here we discuss targeting of specific RTKs as a potential therapeutic strategy for the treatment of thyroid cancer.

Key words: kinase, thyroid, monoclonal antibody, small-molecule inhibitor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-690X(08)00109-7

doi:10.1016/j.beem.2008.09.012

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 1023-1038, December 2008

Article Tools

* Image Usage & Resolution